EGFR and cancer: Metabolic shift toward OXPHOS are considered a distinctive metabolic trait of drug resistance in cancer, while targeting OXPHOS abates resistance to 5-fluorouracil in colon cancer, docetaxel in prostate cancer, MAPK inhibitor in melanoma, and EGFR-TKI in EGFR-driven lung adenocarcinoma (Bosc et al., 2017).